Metastatic Urothelial Carcinoma clinical trials

Explore recruiting metastatic urothelial carcinoma clinical trials.

Recruiting metastatic urothelial carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Urothelial Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

Germany, Greece, Denmark, France, Romania, Poland +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Open-Label, Randomized Study of Livmoniplimab in Combination with Budigalimab Versus Chemotherapy in Subjects with Metastatic Urothelial Carcinoma

Poland, Spain, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. iNDUCT - GETUG V08

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma (MORPHEUS-UC)

France, Greece, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Urothelial Carcinoma trials by city

Metastatic Urothelial Carcinoma clinical trials

Recruiting metastatic urothelial carcinoma studies right now

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

Intervention of Bladder Cancer by CAR-T

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Also recruiting in Europe

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025

A Phase 2, Open-Label, Randomized Study of Livmoniplimab in Combination with Budigalimab Versus Chemotherapy in Subjects with Metastatic Urothelial Carcinoma

Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. iNDUCT - GETUG V08

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma (MORPHEUS-UC)

A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma trials by city

Other conditions